- Home
- ATLC vs FULC Comparison
ATLC vs FULC Comparison
Compare ATLC & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATLC | FULC |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | United States |
| Employees | 417 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 824.8M | 718.4M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | ATLC | FULC |
|---|---|---|
| Price | $52.87 | $7.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $87.50 | $16.38 |
| AVG Volume (30 Days) | 51.4K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $402.57 | N/A |
| Revenue Next Year | $60.95 | N/A |
| P/E Ratio | $9.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $42.03 | $2.32 |
| 52 Week High | $78.91 | $15.74 |
Technical Indicators
Market Signals| Indicator | ATLC | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 41.61 | 33.19 |
| Support Level | $47.31 | $7.40 |
| Resistance Level | $58.86 | $7.64 |
| Average True Range (ATR) | 2.98 | 0.67 |
| MACD | 0.13 | -0.11 |
| Stochastic Oscillator | 9.67 | 2.53 |
Price Performance
Historical ComparisonAbout ATLC Atlanticus Holdings Corporation
Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service (CaaS) and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.